Tony Grist, Gavin Rezos and Stephen Langsford are prolific dealmakers - they share the lessons they've learned over three decades and explain what they look for in new investments.
SPECIAL REPORT: As markets struggle under the pressure of the COVID-19 pandemic, the medtech industry has found itself with an unparalleled, if challenging, opportunity.
SPECIAL REPORT: Despite WA's history of innovative medical research, the state's medtech sector continues to grapple with outsider perceptions and its own commercial direction.
Ardiden has appointed Bradley Boyle as executive director and Michael Stares as general manager – Canadian operations. Mr Boyle was formerly a managing director of Triton Minerals.
US-focused biotech company pSivida has released pricing details of a $US16 million capital raising, after two weeks of volatile trading in its ASX-listed shares.
Shares in biotech company pSivida Corp surged more than 50 per cent today on positive regulatory news from the United States, making up most of the losses it suffered in a dramatic fall in October.
Global drug delivery company, pSivida, has launched a $10 million capital raising, proceeds from which it says will be used for general corporate purposes.
Perth-based biotechnology company pSivida Ltd has sold its food science subsidiary pSiNutria to UK-based venture capital group, Intrinsiq Materials Cayman Ltd, in a deal worth about US$5.18 million ($5.9 million).
Perth-based biotechnology company pSivida Ltd has commenced enrolment for the first studies of absorption, distribution and metabolism of its diabetic macular edema treatment Medidur, the company has announced.
Perth-headquartered bio-nanotech company pSivida Ltd has closed the first tranche of its $21.3 million American Depository Shares and warrants sale, raising $12.5 million through the sale of 9.2 million units.
Perth-headquartered bio-nanotech company pSivida Ltd has sold its subsidiary AION Diagnostics Inc to US-based private equity group GEM Global Yield Fund for around $3.6 million, following the company's float on the Frankfurt Stock Exchange.
Perth-based biotechnology company pSivida Ltd will raise around $11 million through a placement to pay off a convertible note debt, one day after receiving a promise from collaborative partner Pfizer Inc for a further $6.1 million share purchase.
Perth-based biotechnology company pSivida Ltd has signed a collaborative research and license agreement with pharmaceutical giant Pfizer Inc worth $203 million for its drug delivery technologies.
Perth-based biotechnology company pSivida Ltd will raise $11.5 million through a placement to raise funds for working capital in place of a proposed $5.1 million interim investment from Danish group Nordic Biotech Advisors.
Perth-based biotechnology comapny pSivida Ltd has signed a $33.7 million agreement with an unnamed investment fund to finance development of the company's diabetic macular edema treatment.
Two Western Australian companies have cited investment market volatility as a key issue for the failure of their fund raising plans, the first notable setbacks after a period of unprecedented corporate activity.
Directors of Perth headquartered global bio-nanotech company pSivida Ltd have confirmed that they will be taking up rights to subscribe for pSivida shares under their respective individual eligible entitlements to raise approximately $29 million.
Bio-nanotech company pSivida Ltd has announced that Michael Soja has been appointed Vice President, Finance and Chief Financial Officer, and Lori Freedman has been appointed Vice President, Corporate Affairs, General Counsel and Secretary.
Perth headquartered bio-nanotech company pSivida Ltd is looking to raise $29 million through a non-renounceable rights issue to fund clinical trials for two of its treatments.
Perth-based bio-nanotech company pSivida Ltd has entered into an evaluation agreement with a large medical device company to evaluate cardiovascular delivery of drugs using pSivida's drug delivery technologies.
Shares in Western Australia's biggest biotechnology stock, pSivida Ltd, have risen 7 per cent following news that its Retisert product, licensed to Bausch & Lomb, will be co-promoted in the United States by Novartis Ophthalmics.
Nanotechnology company pSivida Ltd has acquired US drug delivery company Control Delivery Systems Inc as part of pSivida's on-going US growth strategy.
Perth biotechnology company pSivida has confirmed the creation of a new spin off, pSiNutria Ltd, a company it will seed with $1.5 million to focus on techology applying to the food industry.
I WOULD like to take this opportunity to distinguish pSivida from the types of problems in moving to foreign exchanges as highlighted by Tim Treadgold in Briefcase (WA Business News, October 13).
PERTH-BASED nano-technology company pSivida Limited has announced that its UK manufacturing partner, Atomising Systems Limited, has completed construction of a dedicated clean-room facility at its She
BIOSILICON company pSiVida has signed a worldwide licence agreement with its UK subsidiary, pSiMedica, for the use of BioSilicon in diagnostics applications as implants in the bodie
